Abstract
The pregnane X receptor (PXR) is a member of the nuclear receptor family of ligand-regulated transcription factors. Like many former orphan nuclear receptors, it contains both DNA and ligand binding domains and binds to response elements in the regulatory regions of target genes as a heterodimer with RXRα. Unlike the vast majority of nuclear receptors, however, PXR responds to a wide variety of chemically distinct xenobiotics and endobiotics, regulating the expression of genes central to both drug and bile acid metabolism. We review the structural basis of PXRs promiscuity in ligand binding, its recruitment of transcriptional coregulators, its potential formation of higher-order nuclear receptor complexes, and its control of target gene expression. Structural flexibility appears to be central to the receptors ability to conform to ligands that differ both in size and shape. We also discuss the clinical implications of PXRs role in the drugdrug interactions, cancer, and cholestatic liver disease.
Keywords: promiscuity, structural flexibility, drug metabolism, polymorphism, cancer, drug interactions, cholestasis, transcription
Current Drug Metabolism
Title: Structure and Function of the Human Nuclear Xenobiotic Receptor PXR
Volume: 6 Issue: 4
Author(s): V. E. Carnahan and M. R. Redinbo
Affiliation:
Keywords: promiscuity, structural flexibility, drug metabolism, polymorphism, cancer, drug interactions, cholestasis, transcription
Abstract: The pregnane X receptor (PXR) is a member of the nuclear receptor family of ligand-regulated transcription factors. Like many former orphan nuclear receptors, it contains both DNA and ligand binding domains and binds to response elements in the regulatory regions of target genes as a heterodimer with RXRα. Unlike the vast majority of nuclear receptors, however, PXR responds to a wide variety of chemically distinct xenobiotics and endobiotics, regulating the expression of genes central to both drug and bile acid metabolism. We review the structural basis of PXRs promiscuity in ligand binding, its recruitment of transcriptional coregulators, its potential formation of higher-order nuclear receptor complexes, and its control of target gene expression. Structural flexibility appears to be central to the receptors ability to conform to ligands that differ both in size and shape. We also discuss the clinical implications of PXRs role in the drugdrug interactions, cancer, and cholestatic liver disease.
Export Options
About this article
Cite this article as:
Carnahan E. V. and Redinbo R. M., Structure and Function of the Human Nuclear Xenobiotic Receptor PXR, Current Drug Metabolism 2005; 6 (4) . https://dx.doi.org/10.2174/1389200054633844
DOI https://dx.doi.org/10.2174/1389200054633844 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Current Medicinal Chemistry Patent Selections
Recent Patents on Regenerative Medicine Differences in the Expression Pattern of mRNA Protein SEMA3F in Endometrial Cancer <i>in vitro</i> under Cisplatin Treatment
Current Pharmaceutical Biotechnology “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry MicroRNA: The Potential Regulator of Endometrial Carcinogenesis
MicroRNA The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women
Current Pharmaceutical Design A New Twist in Cellular Resistance to the Anticancer Drug Bleomycin-A5
Current Drug Metabolism Obesity and Cancer: Biological Links and Treatment Implications
Current Cancer Drug Targets Metabolism and Toxicological Implications of Commonly Used Chemopreventive Drugs Against Breast Cancer/Carcinogenesis
Current Drug Metabolism CRH Receptor Signalling: Potential Roles in Pathophysiology
Current Molecular Pharmacology CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Current Medicinal Chemistry Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Highlights on Important Medicinal Plants for the Menopause Syndrome
Current Women`s Health Reviews Recent Advances in the Rationale Design of GPER Ligands
Current Medicinal Chemistry SERMs: Evolutionary Chemistry, Revolutionary Biology
Current Pharmaceutical Design